Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1975 |
Infigratinib
BGJ-398,NVP-BGJ398 |
Apoptosis; FGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Infigratinib (NVP-BGJ398) 是一种 FGFR 家族抑制剂,抑制 FGFR1,FGFR2,FGFR3和 FGFR4的 IC50分别为 0.9 nM,1.4 nM,1 nM,60 nM。 | |||
T16364 |
Infigratinib phosphate
NVP-BGJ398 phosphate,BGJ-398 phosphate |
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Infigratinib phosphate (BGJ-398 phosphate) 是 FGFR 抑制剂,对 FGFR1,FGFR2 和 FGFR3 的 IC50 分别为0.9,1.4 和 1 nM,比对 FGFR4 和 VEGFR2 的抑制性高40倍,对 Abl,Fyn,Kit,Lck 和 Lyn 几乎无活性。 | |||
T71002 |
Infigratinib acetate
|
||
Infigratinib, also known as, BGJ398 or NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib was approved in 2021 to trea... | |||
T71001 | GSK-598809 | ||
GSK598809 is a selective D(3)R antagonist recently progressed in Phase I trials. GSK-598809 may decrease the rewarding effects of contextual cues associated with drug intake preclinically, which may reduce drug craving in humans. | |||
T71000 |
RO-5328673
|
||
RO-5328673 is a dual NK2/NK3 antagonist. O5328673. [(3)H]RO5328673 bound to a single saturable site on hNK2, hNK3 and gpNK3 with high-affinity. RO5328673 acted as an insurmountable antagonist at both human and guinea-pig NK3 receptors in the [(3)H]IP accumulation assay. In binding kinetic analyses, [(3)H]RO5328673 had fast association and dissociation rates at hNK2 while it had a fast association rate and a remarkably slow dissociation rate at gp and hNK3. In electrophysiological recordings of g... | |||
T71004 | Infigratinib monohydrate | ||
Infigratinib, also known as, BGJ398 or NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib was approved in 2021 to trea... | |||
T71003 |
Infigratinib mesylate
|
||
Infigratinib, also known as, BGJ398 or NVP-BGJ398, is a pan FGFR kinase inhibitor, and is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. pan FGFR kinase inhibitor BGJ398 selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Infigratinib was approved in 2021 to trea... |